Xarelto Lawsuit Plaintiffs Are Encouraged By Similarities To Previously Settled Pradaxa Cases

January 29, 2016 – – BloodThinnerHelp.com reports on similarities between today’s Xarelto lawsuits and previously settled Pradaxa lawsuits, which bring comfort to plaintiffs awaiting Xarelto trials and seeking what they consider to be justice. Xarelto lawsuit numbers continue to regularly increase as the many cases await trial. All Xarelto cases filed in federal courts from across the nation were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). These cases now make up MDL No. 2592 in New Orleans, and are said to involve over 2,800 lawsuits.

The MDL cases for Xarelto are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. The complaints of all cases have been filed against two defendants: Janssen Pharmaceuticals, (a division of the Johnson & Johnson corporation), and Bayer AG. In addition to these nearly 3,000 cases, another 550 Xarelto bleeding lawsuits have been consolidated to form a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.  

Orders given by the Honorable Judge Fallon requested that by January 11th of 2016, 40 bellwether cases be selected to form a bellwether pool from which 4 cases will be chosen to head to representative trials. The judge requested that 10 of the 40 cases be chosen by plaintiffs and 10 of the 40 be chosen by defendants, with the remaining 20 cases to be chosen by the court. As of now, it is expected that these bellwether trials will be heard in the Spring of 2017.

All lawsuits filed against the manufacturers of blood-thinning drug Xarelto similarly claim that it can cause uncontrollable bleeding episodes, both internally or externally, which can prove dangerous or even fatal. A frequent point of contention discussed by lawsuit plaintiffs is that Xarelto manufacturers released their anticoagulant to the public without any accompanying antidote for emergency situations; a decision that plaintiffs call recklessly negligent.

Without an available antidote, if a patient who has taken Xarelto becomes injured and bleeds, doctors may be unable to clot the blood and stop the bleed. These situations call for extreme life-saving measures such as surgeries to drain pools of blood, and blood transfusions. Even a minor bleeding injury can quickly turn into a dangerous and life-threatening situation when someone’s blood cannot clot.

Manufactured by Boehringer Ingelheim in 2010, Pradaxa, like Xarelto, was considered a “new-generation” blood thinner. Within only a short time after its public launch, Pradaxa was the subject of over 3,500 reports of dangerous health complications, more than 750 of which were noted to be fatal. Soon, the drug manufacturers were facing over 4,000 lawsuits regarding their blood thinner. One day prior to trials for these lawsuits, however, Boehringer Ingelheim paid $650 million to plaintiffs in order to settle the suits.

Today, Xarelto plaintiffs find hope in these results. Attorney Joseph Osborne is currently working to ensure that everyone who may have been negatively affected by Xarelto will have the opportunity to fully explore their legal rights. At this time, he is offering free legal consultations to affected individuals. It is believed that those affected may be entitled to legal action and substantial compensation.

To request further information, or ask questions regarding Xarelto bleeding lawsuits, please contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60007807